Drugs / NK521 Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07561437 | Mar 2026 → Apr 2028 expected | cancer | Base Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK521 Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07561437 ↗ |
| Action | Inhibit | “knockout of TIGIT” NCT07561437 ↗ |
| Modality | Cell therapy | “Gene-edited natural killer (NK) cell product” NCT07561437 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT07561437 ↗ |
| Target | TIGIT | “knockout of TIGIT” NCT07561437 ↗ |